Advertisement
Screener

ENDONOVO THERAPEUTICS, INC. (ENDV) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1.6 / 5 stars · 18/56 Roast Me

ENDONOVO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

ENDONOVO THERAPEUTICS, INC. (ENDV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.00 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-04-13.

Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2021-11-19

  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-12-31 was 0.00 shares.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-12-31 was -5.27M shares.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-09-30 was 0.00 shares.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-12-31 was -998.65K shares.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 3.00M shares, a 56718.18% increase from fiscal 2019.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 5.28K shares, a 291.11% increase from fiscal 2018.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 1.35K shares, a 100.00% decline from fiscal 2017.
  • ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 93.20M shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed
2020-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-13
3.00M shares
10-K · filed 2021-04-13
2020-09-303.00M shares
10-Q · filed 2020-11-19
2020-06-1174.67M shares
10-Q · filed 2021-11-19
2019-12-31-5.27M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-13
-5.27M shares
derived: sum of 2 quarters · filed 2021-04-13
5.28K shares
10-K · filed 2021-04-13
2019-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-19
5.28M shares
10-Q · filed 2019-11-19
2019-06-305.28M shares
10-Q · filed 2019-08-13
2018-12-31-998.65K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04
1.35K shares
10-K · filed 2020-05-04
1.35M shares
10-K · filed 2019-04-15
2018-09-301.00M shares
10-Q · filed 2018-11-13
2017-12-310.00 shares
derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-04-15
73.95M shares
derived: sum of 2 quarters · filed 2019-04-15
93.20M shares
10-K · filed 2019-04-15
2017-09-3073.95M shares
derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-11-09
93.20M shares
10-Q/A · filed 2017-11-09
2017-06-3019.25M shares
10-Q · filed 2017-08-10